Alpine Immune Sciences, Inc.

ALPN

N/A

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jul 15, 2026

29w

Drug Pipeline

Drug Name	Phase	Indication	Designations
Placebo (matched to Povetacicept)	Phase 3	Immunoglobulin A Nephropathy	-
Povetacicept	Phase 2	Lupus Nephritis	-
ALPN-101	Phase 2	Systemic Lupus Erythematosus	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

July 2026~Povetacicept

Primary completion for povetacicept trial (NCT05757570) in Immune Thrombocytopenia

Regulatory Approvals

ALPN News